Advertisement

Epigenetic Drivers of Resveratrol-Induced Suppression of Mammary Carcinogenesis: Addressing miRNAs, Protein, mRNA, and DNA Methylation

  • E. R. SauterEmail author
Reference work entry

Abstract

There are both cis- and trans-isomers of resveratrol, with the trans-isomer the more active of the two. Trans-resveratrol is present in a variety of foods, and preclinical data suggest that the agent is effective in both preventing the formation of mammary tumors and in shrinking tumors that have developed. The agent has mild to no human toxicity over a wide dose range. On the other hand, efficacy in humans has not been proven, and first-pass effects through conjugation in the liver have led people to question its clinical usefulness, although evidence of deconjugation intracellularly has also been demonstrated. The epigenetic mechanisms of action of the agent are many, including effects on miRNAs, protein, mRNA, and DNA methylation. Findings to date will be reviewed, with a look to where investigations are headed to better assess clinical efficacy.

Keywords

Trans-resveratrol Cis-resveratrol miRNA DNA methylation mRNA expression Protein expression Glucuronide metabolite Sulfate metabolite 

List of Abbreviations

DNA

Deoxyribonucleic acid

miRNA

microRNA

mRNA

Messenger RNA

RNA

Ribonucleic acid

References

  1. Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107–116CrossRefGoogle Scholar
  2. Berner C, Aumuller E, Gnauck A, Nestelberger M, Just A, Haslberger AG (2010) Epigenetic control of estrogen receptor expression and tumor suppressor genes is modulated by bioactive food compounds. Ann Nutr Metab 57:183–189CrossRefGoogle Scholar
  3. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM (2001) Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61:7456–7463PubMedGoogle Scholar
  4. Brown SA, Sandhu N, Herrmann J (2015) Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nat Rev Clin Oncol 12:718–731CrossRefGoogle Scholar
  5. Cheishvili D, Boureau L, Szyf M (2015) DNA demethylation and invasive cancer: implications for therapeutics. Br J Pharmacol 172:2705–2715CrossRefGoogle Scholar
  6. Chen FP, Chien MH (2014) Phytoestrogens induce differential effects on both normal and malignant human breast cells in vitro. Climacteric 17:682–691CrossRefGoogle Scholar
  7. Colin D, Lancon A, Delmas D, Lizard G, Abrossinow J, Kahn E, Jannin B, Latruffe N (2008) Antiproliferative activities of resveratrol and related compounds in human hepatocyte derived HepG2 cells are associated with biochemical cell disturbance revealed by fluorescence analyses. Biochimie 90:1674–1684CrossRefGoogle Scholar
  8. Dhar S, Hicks C, Levenson AS (2011) Resveratrol and prostate cancer: promising role for microRNAs. Mol Nutr Food Res 55:1219–1229CrossRefGoogle Scholar
  9. Fan Y, Liu L, Fang K, Huang T, Wan L, Liu Y, Zhang S, Yan D, Li G, Gao Y, Lv Y, Chen Y, Tu Y (2016) Resveratrol ameliorates cardiac hypertrophy by down-regulation of miR-155 through activation of breast cancer type 1 susceptibility protein. J Am Heart Assoc 5:e002648PubMedPubMedCentralGoogle Scholar
  10. Gambini J, Ingles M, Olaso G, Lopez-Grueso R, Bonet-Costa V, Gimeno-Mallench L, Mas-Bargues C, Abdelaziz KM, Gomez-Cabrera MC, Vina J, Borras C (2015) Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxidative Med Cell Longev 2015:837042CrossRefGoogle Scholar
  11. Hayashi SI, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, Yoshida N, Yamaguchi Y (2003) The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 10:193–202CrossRefGoogle Scholar
  12. Izzotti A, Cartiglia C, Steele VE, Deflora S (2012) MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res Rev Mutat Res 751:287–303CrossRefGoogle Scholar
  13. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220CrossRefGoogle Scholar
  14. Jannin B, Menzel M, Berlot JP, Delmas D, Lancon A, Latruffe N (2004) Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem Pharmacol 68:1113–1118CrossRefGoogle Scholar
  15. Kala R, Tollefsbol TO (2016) A novel combinatorial epigenetic therapy using resveratrol and pterostilbene for restoring estrogen receptor-alpha (ERalpha) expression in ERalpha-negative breast cancer cells. PLoS One 11:e0155057CrossRefGoogle Scholar
  16. Kala R, Shah HN, Martin SL, Tollefsbol TO (2015) Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent gamma-H2AX and telomerase regulation in triple-negative breast cancer. BMC Cancer 15:672CrossRefGoogle Scholar
  17. Klose RJ, Bird AP (2006) Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31:89–97CrossRefGoogle Scholar
  18. Lancon A, Kaminski J, Tili E, Michaille JJ, Latruffe N (2012) Control of microRNA expression as a new way for resveratrol to deliver its beneficial effects. J Agric Food Chem 60:8783–8789CrossRefGoogle Scholar
  19. Lopez-Serra P, Esteller M (2012) DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 31:1609–1622CrossRefGoogle Scholar
  20. Lubecka K, Kurzava L, Flower K, Buvala H, Zhang H, Teegarden D, Camarillo I, Suderman M, Kuang S, Andrisani O, Flanagan JM, Stefanska B (2016) Stilbenoids remodel the DNA methylation patterns in breast cancer cells and inhibit oncogenic NOTCH signaling through epigenetic regulation of MAML2 transcriptional activity. Carcinogenesis 37:656–668CrossRefGoogle Scholar
  21. Malumbres M (2012) miRNAs and cancer: An epigenetics view. Mol Aspects Med 34:863–874CrossRefGoogle Scholar
  22. Mattiske S, Suetani RJ, Neilsen PM, Callen DF (2012) The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomark Prev 21:1236–1243CrossRefGoogle Scholar
  23. Mccormack D, Mcfadden D (2013) A review of pterostilbene antioxidant activity and disease modification. Oxidative Med Cell Longev 2013:575482CrossRefGoogle Scholar
  24. Mgbonyebi OP, Russo J, Russo IH (1998) Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12:865–869PubMedGoogle Scholar
  25. Osman AM, Telity SA, Damanhouri ZA, Al-Harthy SE, Al-Kreathy HM, Ramadan WS, Elshal MF, Khan LM, Kamel F (2015) Chemosensitizing and nephroprotective effect of resveratrol in cisplatin -treated animals. Cancer Cell Int 15:6CrossRefGoogle Scholar
  26. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, Brown K (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70:7392–7399CrossRefGoogle Scholar
  27. Qin W, Zhu W, Sauter ER (2005) Resveratrol induced DNA methylation in ER+ breast cancer. Proc Am Assoc Cancer Res 96:2750AGoogle Scholar
  28. Qin W, Zhu W, Zhang K, Clarke K, Sauter ER (2012) Resveratrol decreases tumor formation in a human relevant animal model of breast cancer. In: 11th annual conference, Frontiers of Cancer Prevention Research, A36Google Scholar
  29. Qin W, Zhang K, Clarke K, Weiland T, Sauter ER (2014) Methylation and miRNA effects of resveratrol on mammary tumors vs. normal tissue. Nutr Cancer 66:270–277CrossRefGoogle Scholar
  30. Rai G, Mishra S, Suman S, Shukla Y (2016) Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: a mechanistic insight. Phytomedicine 23:233–242CrossRefGoogle Scholar
  31. Ronghe A, Chatterjee A, Singh B, Dandawate P, Abdalla F, Bhat NK, Padhye S, Bhat HK (2016) 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, 1 a novel resveratrol analog, differentially regulates estrogen receptors alpha and beta in breast cancer cells. Toxicol Appl Pharmacol 301:1–13CrossRefGoogle Scholar
  32. Santner SJ, Feil PD, Santen RJ (1984) In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 59:29–33CrossRefGoogle Scholar
  33. Singh B, Shoulson R, Chatterjee A, Ronghe A, Bhat NK, Dim DC, Bhat HK (2014) Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways. Carcinogenesis 35:1872–1880CrossRefGoogle Scholar
  34. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ (1998) Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273:21875–21882CrossRefGoogle Scholar
  35. Subbaramaiah K, Sue E, Bhardwaj P, Du B, Hudis CA, Giri D, Kopelovich L, Zhou XK, Dannenberg AJ (2013) Dietary polyphenols suppress elevated levels of proinflammatory mediators and aromatase in the mammary gland of obese mice. Cancer Prev Res (Phila) 6:886–897CrossRefGoogle Scholar
  36. Sun B, Hoshino J, Jermihov K, Marler L, Pezzuto JM, Mesecar AD, Cushman M (2010) Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem 18:5352–5366CrossRefGoogle Scholar
  37. Suzuki H, Maruyama R, Yamamoto E, Kai M (2012) DNA methylation and microRNA dysregulation in cancer. Mol Oncol 6:567–578CrossRefGoogle Scholar
  38. Veeck J, Esteller M (2010) Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 15:5–17CrossRefGoogle Scholar
  39. Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R (2004) Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci 93:2448–2457CrossRefGoogle Scholar
  40. Zhu W, Qin W, Zhang K, Rottinghaus GE, Chen YC, Kliethermes B, Sauter ER (2012) Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer 64:393–400CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hartford HealthCare Cancer InstituteHartfordUSA

Personalised recommendations